These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32096871)

  • 61. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma.
    Barlin JN; Jelinic P; Olvera N; Bogomolniy F; Bisogna M; Dao F; Barakat RR; Chi DS; Levine DA
    Gynecol Oncol; 2013 Mar; 128(3):512-7. PubMed ID: 23168173
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.
    Beltrame L; Di Marino M; Fruscio R; Calura E; Chapman B; Clivio L; Sina F; Mele C; Iatropoulos P; Grassi T; Fotia V; Romualdi C; Martini P; Noris M; Paracchini L; Craparotta I; Petrillo M; Milani R; Perego P; Ravaggi A; Zambelli A; Ronchetti E; D'Incalci M; Marchini S
    Ann Oncol; 2015 Jul; 26(7):1363-71. PubMed ID: 25846551
    [TBL] [Abstract][Full Text] [Related]  

  • 63. STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.
    Permuth-Wey J; Fulp WJ; Reid BM; Chen Z; Georgeades C; Cheng JQ; Magliocco A; Chen DT; Lancaster JM
    Int J Cancer; 2016 Feb; 138(3):612-9. PubMed ID: 26264211
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
    [TBL] [Abstract][Full Text] [Related]  

  • 67. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
    Ghaffari A; Peterson N; Khalaj K; Vitkin N; Robinson A; Francis JA; Koti M
    Br J Cancer; 2018 Aug; 119(4):440-449. PubMed ID: 30046165
    [TBL] [Abstract][Full Text] [Related]  

  • 68. miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
    Panoutsopoulou K; Avgeris M; Magkou P; Mavridis K; Dreyer T; Dorn J; Obermayr E; Reinthaller A; Michaelidou K; Mahner S; Vergote I; Loverix L; Braicu I; Sehouli J; Zeillinger R; Magdolen V; Scorilas A
    Int J Cancer; 2020 Dec; 147(12):3560-3573. PubMed ID: 32621752
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
    Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
    Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma.
    Romeo M; Karachaliou N; Chaid I; Queralt C; De Aguirre I; Del Carmen Gómez M; Sanchez-Ronco M; Radua J; Ramírez JL; Rosell R
    Int J Biol Markers; 2017 Mar; 32(1):e90-e95. PubMed ID: 27443420
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N
    J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480
    [TBL] [Abstract][Full Text] [Related]  

  • 73. FANCD2 expression affects platinum response and further characteristics of high grade serous ovarian cancer in cells with different genetic backgrounds.
    Taylor SJ; Hollis RL; Gourley C; Herrington CS; Langdon SP; Arends MJ
    Exp Mol Pathol; 2024 Aug; 138():104916. PubMed ID: 38959632
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Who are the long-term survivors of high grade serous ovarian cancer?
    Hoppenot C; Eckert MA; Tienda SM; Lengyel E
    Gynecol Oncol; 2018 Jan; 148(1):204-212. PubMed ID: 29128106
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.
    Berkel C; Cacan E
    Hum Cell; 2021 May; 34(3):862-877. PubMed ID: 33576947
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
    Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
    Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
    Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
    Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
    Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
    Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
    [TBL] [Abstract][Full Text] [Related]  

  • 80. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
    Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
    BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.